Home › Funds › Aisling Capital Management LP › BBOT
Aisling Capital Management LP position in BBOT
BRIDGEBIO ONCOLOGY THERAPEUT · Health Care
Aisling Capital Management LP reported holding 1,018,018 shares of BBOT (BRIDGEBIO ONCOLOGY THERAPEUT) in its Q3 2026 13F filing — a position valued at US$4.1M, representing 1.38% of its reported portfolio and ranking #7 among its reported holdings. Aisling Capital Management LP has disclosed BBOT holdings in 5 of the last 5 reported quarters, going back to Q3 2025.
Last updated: 2026-11-13 · Source: SEC EDGAR Form 13F-HR
How Aisling Capital Management LP's BBOT position evolved
Aisling Capital Management LP first disclosed a stake in BBOT in Q3 2025 at 564,625 shares (US$6.5M). The position peaked in Q1 2026 at 1,018,018 shares, worth US$9.1M. Across 5 filings, Aisling Capital Management LP increased the stake 1 time(s), trimmed it 0 time(s) and left it unchanged 3 time(s). The most recent filing (Q3 2026) shows 1,018,018 shares valued at US$4.1M. Notable position changes include a 80% increase in Q1 2026 (shares fell 15% over the following quarter).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q3 2025 | 564.62K | $6.54M | New |
| Q4 2025 | 564.62K | $7.07M | Hold |
| Q1 2026 | 1.02M | $9.11M | Add |
| Q2 2026 | 1.02M | $7.76M | Hold |
| Q3 2026 | 1.02M | $4.14M | Hold |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About BBOT and 13F data
BBOT (BRIDGEBIO ONCOLOGY THERAPEUT) is a Health Care company. 81 other funds we track also report a position in BBOT — the largest reported positions include Cormorant Asset Management, LP (US$136.2M), DEERFIELD MANAGEMENT COMPANY, L.P. (US$37.2M), Omega Fund Management, LLC (US$25.1M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding BBOT
- Cormorant Asset Management, LP 17.88M sh · $136.23M · Q2 2026
- DEERFIELD MANAGEMENT COMPANY, L.P. 4.89M sh · $37.23M · Q2 2026
- Omega Fund Management, LLC 3.29M sh · $25.07M · Q2 2026
- EcoR1 Capital, LLC 2.82M sh · $21.51M · Q2 2026
- Enavate Sciences GP, LLC 2.63M sh · $20.02M · Q2 2026
- Novo Holdings A/S 2.25M sh · $17.14M · Q2 2026
- Alphabet Inc. 2.82M sh · $11.57M · Q3 2026
- REGENTS OF THE UNIVERSITY OF CALIFORNIA 2.51M sh · $10.29M · Q3 2026
- Opaleye Management Inc. 700.00K sh · $5.33M · Q2 2026
- Catalio Capital Management, LP 318.41K sh · $2.43M · Q2 2026
- Casdin Capital 282.31K sh · $2.15M · Q2 2026
- Avidity Partners Management LP 43.85K sh · $334.16K · Q2 2026
More on Aisling Capital Management LP
FAQ
How long has Aisling Capital Management LP held BBOT?
Aisling Capital Management LP has disclosed BBOT holdings in 5 of the last 5 reported quarters, going back to Q3 2025.
What is Aisling Capital Management LP's current position in BBOT?
As of Q3 2026, Aisling Capital Management LP holds 1.02M shares of BBOT (BRIDGEBIO ONCOLOGY THERAPEUT), valued at $4.14M, representing 1.38% of its reported portfolio and ranking #7.
Has Aisling Capital Management LP been buying or selling BBOT?
In the latest 13F filing (Q3 2026), Aisling Capital Management LP held unchanged its position in BBOT. The position peaked in Q1 2026 at 1.02M shares.
Which other funds hold BBOT?
Other major institutional holders of BBOT include Cormorant Asset Management, LP, DEERFIELD MANAGEMENT COMPANY, L.P., Omega Fund Management, LLC, among 81 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.